Every S-1 that Corgi IP Licensing & Royalties ETF (PTNT) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A S-1 covers the registration statement a company files to sell shares publicly, so if you follow PTNT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PTNT filings page.
Palatin Technologies, Inc. filed Amendment No. 2 to a Form S-1 for a firm-commitment public offering of 2,307,692 shares of common stock, each sold with a Series J warrant to purchase one share and a Series K warrant to purchase one share. The filing also registers an alternative of up to 2,307,692 pre-funded warrants in lieu of shares, 46,153 underwriter warrants, and the shares underlying all such warrants.
The expected combined offering price range is $6.00–$7.00 (assumed $6.50 midpoint). Underwriting discounts are 7.0%, with a 45‑day over‑allotment option for up to 346,153 additional shares and accompanying warrants. Estimated net proceeds are approximately $13.9 million at the assumed price, intended for working capital and development of MC4R obesity programs. Closing is conditioned on re‑listing the common stock on NYSE American.
Holders unable to exceed ownership caps may elect pre‑funded warrants with a $0.0001 exercise price, subject to 4.99% (or 9.99%) beneficial ownership limits. Shares outstanding were 973,291 as of October 16, 2025.
Palatin Technologies, Inc. filed Amendment No. 1 to its Form S-1 registration statement as an exhibits-only update to add an executed auditor consent as Exhibit 23.2. The company states that no additional securities are being registered under this amendment and that all applicable registration fees were previously paid.
The filing also details estimated offering expenses totaling $103,989.31, including SEC registration, legal, accounting and miscellaneous costs. It restates indemnification provisions for directors and officers under Delaware law and lists various unregistered warrant and preferred stock transactions over the past three years, including cash warrant exercises that generated gross proceeds of approximately $3.4 million and $6.1 million, and a 2022 preferred stock financing in which $15,000,000 of proceeds was later redeemed in cash for $15,750,000.
Palatin Technologies, Inc. (PTNT) discloses limits on share issuances tied to its offering and regulatory milestones. The company agreed not to enter into or issue shares under a variable rate transaction for four months after the offering, but will be permitted to make sales under an "at-the-market offering" sales agreement beginning on the 46th day following completion of the offering. Certain termination dates for agreements are tied to the U.S. Food and Drug Administration's acceptance of the company’s investigational new drug applications for an in-house obesity treatment (long-acting peptide or oral small molecule), with fallback termination calendar dates of May 8, 2027 and May 8, 2030. The filing also lists specific calendar dates in mid-to-late 2025: July 9, July 29, August 8 (amended August 11), August 18, September 10, and September 22, 2025.